BriaCell Chosen to Showcase Phase 2 and 3 Clinical Findings at SABCS® 2025

BriaCell's Presentations: BriaCell Therapeutics will present three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium, showcasing key biomarker data and survival results from their studies on Bria-IMT™ and other therapies for metastatic breast cancer.

Significant Data Sharing: The presentations include late-breaking clinical posters that aim to provide substantial data to leading breast cancer experts, with the goal of improving clinical outcomes for cancer patients.

Poster Details: Key presentations include the impact of prior therapy and biomarkers in the Bria-ABC Phase 3 Trial, survival results from the Phase II Bria-IMT vaccine, and cytokine signatures as biomarkers of clinical benefit in breast cancer vaccination.

Company Overview: BriaCell is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance cancer care, with more information available on their website.